Institutional members access full text with Ovid®

Share this article on:

Current opinions in the infection control of carbapenem-resistant Enterobacteriaceae species and Pseudomonas aeruginosa

Gholizadeh, Pouryaa,b; Maftoon, Hamidehc; Aghazadeh, Mohammada; Asgharzadeh, Mohammadc; Kafil, Hossein Samadid

Reviews in Medical Microbiology: July 2017 - Volume 28 - Issue 3 - p 97–103
doi: 10.1097/MRM.0000000000000107
Microbiology

Pseudomonas aeruginosa and some of the species of Enterobacteriaceae are Gram-negative hospital-acquired pathogens that are mostly difficult to treat. Carbapenem drugs are a group of β-lactams class that affect cell wall and are administered in the treatment of infections caused by these organisms. These organisms can be resistant to carbapenem drugs via mechanisms such as carbapenemase enzymes and multidrug efflux systems. Detection methods for carbapenem-resistant isolates are the modified Hodge test, Carba NP test, and PCR. This review will describe the current opinion in the treatment of multidrug-resistant and carbapenemase-producing Enterobacteriaceae and P. aeruginosa and suggest some available antibiotics to be administered in the treatment of infections involving these organisms. Based on carbapenem susceptibility patterns found in previous studies, some drugs such as antipseudomonal agents, colistin, or combined therapy have been suggested for carbapenemase-producing P. aeruginosa, and tigecycline, colistin, and fosfomycin have been suggested for carbapenemase-producing Enterobacteriaceae.

aInfectious and Tropical Medicine Research Center

bStudent Research Committee

cHematology and Oncology Research Center

dDepartment of Medical Microbiology and Virology, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Correspondence to Hossein Samadi Kafil, PhD, Assistant Professor, Department of Medical Microbiology and Virology, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. E-mail: Kafilhs@tbzmed.ac.ir

Received 26 October, 2016

Revised 19 March, 2017

Accepted 21 March, 2017

Copyright © Wolters Kluwer Health, Inc. All rights reserved.